Brought to you by 
Spark licenses exclusive rights to Selecta's SVP platform for up to five targets
16 Mar 2018
Executive Summary
Selecta Biosciences Inc. granted Spark Therapeutics Inc. exclusive global rights to use its Synthetic Vaccine Particles (SVP) technology for co-administration with up to five gene therapy targets, the first of which is FVIII for hemophilia A. Spark has exclusive options for four additional targets; therapy areas were not disclosed.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Spark licenses exclusive rights to Selecta's SVP platform for up to five targets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice